Jake A Kushner
Overview
Explore the profile of Jake A Kushner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
3701
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Argaw P, Kushner J, Kohane I
AMIA Jt Summits Transl Sci Proc
. 2023 Jun;
2023:32-41.
PMID: 37350904
Diabetes is associated with heterogeneous behaviors affecting patients' clinical characteristics and trajectories. This study includes 21,288 patients with type 2 diabetes (women, ages 30 to 65). The cohort was filtered...
2.
Peters A, McGuire D, Danne T, Kushner J, Rodbard H, Dhatariya K, et al.
Diabetes Care
. 2020 Sep;
43(11):2713-2720.
PMID: 32928957
Objective: To evaluate the incidence and risk factors for diabetic ketoacidosis (DKA) and related adverse events (AEs) in adults with type 1 diabetes treated with sotagliflozin adjunctive to insulin. Research...
3.
Bode B, Cengiz E, Wadwa R, Banks P, Danne T, Kushner J, et al.
Diabetes Technol Ther
. 2020 Jul;
23(1):59-69.
PMID: 32640846
Young adults with type 1 diabetes (T1D) tend to have higher A1C than older adults and are at increased risk for diabetic ketoacidosis (DKA). Oral adjuncts to insulin have not...
4.
Kushner J
Nutrients
. 2019 Nov;
11(11).
PMID: 31703469
I read with great interest the thoughtful review concerning the potential impact of carbohydrate restriction in type 1 diabetes on glycaemic parameters and athletic performance [...].
5.
Ahn S, Granger A, Rankin M, Lam C, Cox A, Kushner J
PLoS One
. 2019 Sep;
14(9):e0214829.
PMID: 31490929
Tamoxifen is a mixed agonist/antagonist estrogen analogue that is frequently used to induce conditional gene deletion in mice using Cre-loxP mediated gene recombination. Tamoxifen is routinely employed in extremely high-doses...
6.
Baker C, Wason S, Banks P, Sawhney S, Chang A, Danne T, et al.
Diabetes Obes Metab
. 2019 Jul;
21(11):2440-2449.
PMID: 31264767
Aims: To assess the dose-related effects of sotagliflozin, a novel dual inhibitor of sodium-glucose co-transporters-1 and -2, in type 1 diabetes (T1D). Materials And Methods: In this 12-week, multicentre, randomized,...
7.
Kohn J, Rajan S, Kushner J, Fox K
Pediatr Diabetes
. 2019 May;
20(6):769-777.
PMID: 31125158
Background And Objective: Adolescence and pregestational diabetes separately increase risks of adverse pregnancy outcomes, but little is known about their combined effect. To analyze pregnancy outcomes, healthcare utilization, and expenditures...
8.
Pettus J, Kushner J, Valentine V, Wood R, Pang C, Paranjape S, et al.
Diabetes Technol Ther
. 2019 May;
21(6):336-343.
PMID: 31095422
Adjunct therapy can help patients with type 1 diabetes achieve glycemic goals while potentially mitigating some of the side effects of insulin. In this study, we used a patient survey...
9.
Hallberg S, Dockter N, Kushner J, Athinarayanan S
Diabetes Obes Metab
. 2019 Apr;
21(8):1769-1779.
PMID: 30941880
Aims: The global rate of type 2 diabetes (T2D) continues to rise. Guidelines that influence the worldwide treatment of this disease are central to changing this trajectory. We sought in...
10.
Lam C, Rankin M, King K, Wang M, Shook B, Kushner J
Diabetes
. 2019 Mar;
68(5):963-974.
PMID: 30833466
Glucagon-containing α-cells potently regulate glucose homeostasis, but the developmental biology of α-cells in adults remains poorly understood. Although glucagon receptor antagonists (GRAs) have great potential as antidiabetic therapies, murine and...